

# POWERING AFFORDABLE CARE

with drug monitoring services that help  
to ensure patient compliance and  
identify potential drug misuse



## Quest Diagnostics Clinical Drug Monitoring

Quest Diagnostics is a trusted laboratory committed to providing responsible, cost-conscious clinical drug monitoring services for pain specialists.

Our approach, tools, and technologies help minimize overtesting.

We efficiently deliver insights that can help you and your patients make more informed decisions.



A trusted leader in diagnostic testing for more than 50 years



State-of-the-art testing with enhanced sensitivity



MDs, PhDs, and toxicologists to help with results interpretation



Comprehensive, state-of-the-art test menu

### Meeting the needs of pain specialists

Quest Diagnostics offers a clinical drug monitoring solution that addresses the needs of pain specialists:

- Fast turnaround time to facilitate timely insights
- Clinical drug testing to monitor patients for adherence to a medication regimen
- Insights that help identify dangerous drug combinations such as opioids + benzodiazepines + alcohol
- Broad presumptive test offerings to quickly rule out multiple drug classes before conducting definitive tests
- Definitive testing for confirmation of positive presumptive results and for testing where presumptive tests are not available

We deliver information that broadens diagnostic insights and brings them to the fight against the drug misuse epidemic. Working together, we can help ensure your patients get access to the care they need.

### One lab provider for all your testing needs

- **A comprehensive portfolio** of drug tests to identify the presence of prescribed, nonprescribed, and illicit drugs
- A broad menu of **more than 3,500 tests that spans the continuum of care**, including liver and renal function, nutritional markers, thyroid and other hormones, and infectious disease
- **Oral fluid** as an alternative to urine



## State-of-the-art technologies for accurate, reliable testing

- Presumptive: enhanced immunoassay sensitivity, with **lower cutoff values to better detect benzodiazepines and opioids**
  - Definitive: **liquid chromatography coupled with mass spectrometry (LC-MS/MS)**
- 

## A drug testing company that's easy to work with

- Seamlessly **integrate with over 600 EHRs** to help drive efficiency
- **Quantum® for Healthcare Professionals** helps deliver more efficient patient care, foster better interactions with patients, and reduce the practice workload
  - Lab test ordering in just 3 clicks
  - Easy order tracking
  - Schedule courier specimen pickup online
- **Easy-to-read physician and patient reports**



## Balancing care with the cost of clinical drug monitoring

We believe **good clinical care should be balanced by cost control.**

Presumptive tests can be performed on multiple drug classes before reflexing to the more costly definitive tests to confirm presumptive-positive or unexpected presumptive-negative results. This 2-step testing process has the potential to balance clinical care with cost control.<sup>1,2</sup>

**We're in-network for >92% of lives nationwide and have preferred lab network status with major health plans.**

In addition, we offer financial assistance programs to qualified patients to help keep patients' costs low.

## Clinical Drug Monitoring test list

Quest Diagnostics offers a comprehensive menu of tests for prescription, illicit, and designer drugs.

Our flexible testing solutions let you choose the right test for each patient. We offer:

- Presumptive testing
- Presumptive with reflex to definitive testing
- Definitive testing

### Our broad test menu covers the following drugs and drug metabolites:

|                                      |                             |                           |
|--------------------------------------|-----------------------------|---------------------------|
| Alcohol Metabolites                  | Eszopiclone                 | Opiates                   |
| Amphetamines                         | Fentanyl                    | Oxycodone                 |
| Amphetamines with Reflex d/l Isomers | Gabapentin                  | Phencyclidine             |
| Antidepressants                      | Heroin Metabolite           | Pregabalin                |
| Antipsychotics (urine)               | Marijuana Metabolite        | Propoxyphene              |
| Antipsychotics (serum)               | MDMA/MDA                    | Synthetic Cannabinoids    |
| Barbituates                          | Meperidine                  | Synthetic Stimulants      |
| Benzodiazepines                      | Methadone Metabolite        | Tapentadol                |
| Buprenorphine with Naloxone          | Methamphetamine d/l Isomers | Tramadol                  |
| Carisoprodol                         | Methylphenidate             | Tricyclic Antidepressants |
| Cocaine Metabolite                   | Mitragynine                 | Zolpidem                  |
|                                      | Naltrexone                  |                           |

## Presumptive testing: comparing options

Presumptive drug tests are used to identify possible use or non-use of a drug or a drug class. Examples of presumptive testing include laboratory instrument chemistry immunoassays (IA) and analyzers, as well as point of care (POC) devices.<sup>2</sup> Below are key differences between POC devices and laboratory IA methods.

### POC presumptive tests

- POC tests are inexpensive and produce results within minutes
- POC presumptive devices are typically limited by high cutoff values that cannot be modified to enhance detection of commonly used substances, such as benzodiazepines and opiates<sup>2,3</sup>
- POC methodology exhibits variable sensitivity and specificity across drug class<sup>1,2</sup>

### Quest laboratory IA presumptive tests

- Our laboratory presumptive IA methods have been modified with lower cutoff values to enhance sensitivity and better identify commonly used drug classes, such as benzodiazepines and opioids<sup>2</sup>

## At-a-glance interpretation of drug test results



When you order a drug test, you can select the medMATCH<sup>®</sup> test option. Our medMATCH reports indicate whether the prescribed drug(s), as specified by the ordering provider, or other drugs are detected in a specimen.

Quarterly Trending Reports give you a summary of your practice's positivity.





## Take advantage of our medMATCH® reports

Our medMATCH reports are designed to provide actionable insights with the goal of “at-a-glance” interpretation. The reports provide a summary of your patient’s consistent and inconsistent results for prescribed drugs, and also include reporting on nonprescribed, inconsistent drugs. This allows you to have a complete view of drugs that your patient is taking, address any noncompliance issues, and alerts you of any potential drug misuse or dangerous drug combinations.

medMATCH reports offer providers an intuitive, streamlined process from ordering to the delivery of the final report.



| medMATCH® Drug Monitoring Report  |  |  |  |
|---|--|--|--|
| medMATCH Summary  |  |  |  |
| medMATCH indicates presence or absence of prescribed and non prescribed drugs. Prescribed drugs are provided by the ordering clinician. |  |  |  |
| Legend  | Prescribed Consistent<br>Drugs prescribed and detected | Prescribed Inconsistent<br>Drugs prescribed but not detected | Not Prescribed Inconsistent<br>Drugs detected but not prescribed |
| ✓ = Consistent  |  |  |  |
| ✗ = Inconsistent  | ✓ = Buprenorphine Nalox                                | ✗ = Gabapentin   | ✗ = Ethyl Sulfate (ETS)  |
| ◆ = Prescribed  |  |  |  |
| Prescriptions reported by client with no testing ordered: Zolpidem  |  |  |  |
| DRUG MONITORING, PANEL 8 WITH CONFIRMATION, URINE   |  |  |  |
| Alcohol Metabolites   | POSITIVE   | 500 ng/mL  |  |
| Ethyl Glucuronide (ETG)   | NEGATIVE   | 500 ng/mL  |  |
| Ethyl Sulfate (ETS)   | 100  | 100 ng/mL  | ✗ INCONSISTENT   |
| Alcohol Metab Comments: See Alcohol Metab Notes, LDT Notes  |  |  |  |
| Amphetamines  | NEGATIVE   | 500 ng/mL  |  |
| Benzodiazepines   | NEGATIVE   | 100 ng/mL  |  |
| Buprenorphine   | POSITIVE   | 5 ng/mL  |  |
| ◆ Buprenorphine   | 101  | 2 ng/mL  | ✓ CONSISTENT   |
| ◆ Norbuprenorphine  | 105  | 2 ng/mL  | ✓ CONSISTENT   |
| ◆ Naloxone  | 110  | 2 ng/mL  | ✓ CONSISTENT   |
| Buprenorphine Comments: See Buprenorphine Notes, LDT Notes  |  |  |  |

medMATCH Summary expanded to 3 categories

Alerts clinician to non-tested prescription drugs

Inconsistent results are flagged


Drug-class-specific notes and lab-developed test (LDT) notes are consolidated and listed at the end of report

Consistent results for prescribed drugs are flagged

## Oral-Eze®: When you need an alternative

Quest Diagnostics knows that your needs change, and having more choices benefits you and your patients when monitoring for the presence of drugs. For those situations when urine collection is not practical, you now have an alternative—oral fluid.

Oral-Eze® oral fluid collection takes approximately 5 minutes, **reducing time in the office and improving patient convenience.**



## Drug toxicology consultation

### Our experts are available by phone:

- **Drug monitoring menu, options, and services**—discuss test selection, sample requirements, and whether or not to choose medMATCH
- **Drug monitoring results inquiries and interpretation**—discuss basic results interpretation, consider adding additional substances to the test, or request repeats
- **Drug monitoring consultation scheduling**—schedule a call with appropriate experts on more complex questions



1.877.40.RXTOX (1.877.407.9869) | Monday-Friday, 8:00 AM–10:00 PM EST

Learn more by talking with your sales representative or visit [QuestDrugMonitoring.com](https://www.questdiagnostics.com/questdrugmonitoring).

#### References

1. Centers for Medicare and Medicaid Services. Local coverage determination (LCD): controlled substance monitoring and drugs of abuse testing (L35724). Updated April 8, 2021. Accessed September 8, 2021. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=35724&ver=68&bc=CAAAAAAAAAA>
2. Kirsh KL, Heit HA, Huskey A, et al. Trends in drug use from urine drug testing of addiction treatment clients. *J Opioid Manag*. 2015;11(1):61-68. doi:10.5055/jom.2015.0253
3. Hurford M, Cohen P, Giles L, et al. Consensus statement: appropriate use of drug testing in clinical addiction medicine. American Society of Addiction Medicine. Published April 5, 2017. Accessed September 8, 2021. [https://www.asam.org/docs/default-source/quality-science/the-asam-appropriate-use-of-drug-testing-in-clinical-addiction-medicine-full-document.pdf?Status=Temp&sfvrsn=700a7bc2\\_2](https://www.asam.org/docs/default-source/quality-science/the-asam-appropriate-use-of-drug-testing-in-clinical-addiction-medicine-full-document.pdf?Status=Temp&sfvrsn=700a7bc2_2)

Image content features models and is intended for illustrative purposes only.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners.  
© 2021 Quest Diagnostics Incorporated. All rights reserved. SB7870 9/2021

